The stock has a very, very low float and the price has been rising on just a little volume. It is not unrealistic to
think that the stock could soar and see $15 -$20 range on the news (based on our own technical analysis).
In May, SIGA announced that it had submitted its response to the Biomedical Advance Research and
Development Authority (BARDA) regarding the agency's outstanding RFP for the procurement of 1.7
million courses of a smallpox antiviral.
The U.S. government considers the inhaled smallpox virus the single biggest biological threat which could
be used against Americans via a terrorist attack.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the
design and development of novel products for the prevention and treatment of serious infectious diseases,
with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development
of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has
antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo,
Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).
Please learn more about the company here: http://www.siga.com/
No comments:
Post a Comment